The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer. The main questions it aims to answer are: * To determine protective effect of metformin on structural and functional kidney injury caused by cisplatin in patients with bladder cancer. * To evaluate the safety of combining cisplatin and metformin on patients with bladder cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Non-diabetic adults of age between 18 to 65.
• Chemotherapy naïve patients diagnosed with bladder cancer.
• Patients with stable renal function: eGFR is above 60 ml/min/1.73 m2
Locations
Other Locations
Egypt
faculty of pharmacy Cairo university
RECRUITING
Cairo
Contact Information
Primary
Samah Essam Saber Mahran
samah.essam@pharma.cu.edu.eg
0201094164048
Time Frame
Start Date: 2023-06-01
Estimated Completion Date: 2024-12-30
Participants
Target number of participants: 78
Treatments
Active_comparator: Metformin
(39) patients taking metformin (500 mg twice daily) with cisplatin (70 mg/m2) and gemcitabine (1000 mg/m2) (GC) protocol
No_intervention: Control
(39) patients taking cisplatin (70 mg/m2) gemcitabine (1000 mg/m2) (GC) protocol without metformin
Related Therapeutic Areas
Sponsors
Leads: Cairo University